MERUS N.V. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 40.31 USD | -2.33% |
|
-5.93% | +46.58% |
| Mar. 28 | Truist Securities Initiates Coverage on Merus With Buy Rating, $69 Price Target | MT |
| Mar. 07 | Needham Raises Price Target on Merus to $66 From $65, Maintains Buy Rating | MT |
Chart calendar Merus N.V.
585ba65fcc85fbef33.0XsRw1UZTrwgt8FSZ3YjAEN0ecWQKlsRdJa1OZZ1FVY.niF7tiFMPv559IkADBMSMTMYHqLmX293BMaMb_wAVgmFEF-neCsqhEWCjA~2750106e763278134800620e1fe05518
Upcoming events on Merus N.V.
Past events on Merus N.V.
| 2024-04-10 08:45 am | Needham Healthcare Conference |
| 2024-04-08 12:00 pm | American Association for Cancer Research Meeting - Abstract No : 1903 |
| 2024-03-11 12:00 pm | Leerink Partners Global Biopharma Conference |
| 2024-02-28 04:15 pm | Q4 2023 Earnings Release |
| 2024-02-22 09:00 am | Citi Oncology Leadership Summit |
| 2024-02-07 02:30 pm | Guggenheim Healthcare Talks Biotechnology Conference |
| 2023-12-03 04:50 am | European Society for Medical Oncology Congress - Poster Number: #362P |
| 2023-12-02 08:40 pm | European Society for Medical Oncology Congress - Poster Number: #516MO |
| 2023-12-02 04:50 am | European Society for Medical Oncology Congress - Presentation Number #: 362P |
| 2023-12-02 04:50 am | European Society for Medical Oncology Congress - Poster Number: 595P# |
| 2023-11-30 | European Society for Medical Oncology Congress |
| 2023-11-27 08:00 am | Investor Meeting |
| 2023-11-14 01:15 pm | Stifel Healthcare Conference |
| 2023-11-08 11:30 am | BMO BioPharma Spotlight Series: Oncology |
| 2023-11-01 04:12 pm | Q3 2023 Earnings Release |
| 2023-10-23 03:00 am | European Society for Medical Oncology Congress - Poster Session 1618P |
| 2023-10-21 | European Society for Medical Oncology Congress - Poster Session 1618P |
| 2023-10-21 03:35 am | European Society for Medical Oncology Congress - Oral No - 1315MO |
| 2023-10-16 07:30 am | Business Update Call |
| 2023-09-13 12:55 pm | Morgan Stanley Global Healthcare Conference |
Annual results
| Fiscal Period | December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 31,1 32,2 -3.35% | 29,9 28,5 5.03% | 49,1 46,2 6.22% | 41,6 40,1 3.82% | 43,9 45,1 -2.57% | 38,9 |
|
EBITDA Million USD | Released Forecast Spread | -57,5 -62,6 8.17% | 0,00 0,00 - | -88,7 -91,6 3.13% | -159 -152 -4.89% | -154 -152 -1.5% | -192 |
|
EBIT Million USD | Released Forecast Spread | -58,7 -50,5 -16.04% | -75,9 -72,8 -4.22% | -90,0 -93,3 3.61% | -160 -151 -6.28% | -157 -151 -3.4% | -199 |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -55,0 -42,4 -29.52% | -85,0 -74,9 -13.46% | -66,6 -80,1 16.87% | -130 -89,1 -46.24% | -152 -133 -13.82% | -182 |
|
Net income Million USD | Released Forecast Spread | -55,2 -42,8 -28.85% | -85,5 -75,2 -13.74% | -66,8 -78,8 15.16% | -131 -89,3 -46.88% | -155 -133 -16.52% | -188 |
|
EPS USD | Released Forecast Spread | -2,28 -1,73 -31.78% | -2,92 -2,64 -10.79% | -1,73 -2,09 17.28% | -2,92 -2,09 -39.98% | -3,00 -2,63 -13.96% | -3,19 |
| Announcement Date | 12/03/20 | 16/03/21 | 28/02/22 | 28/02/23 | 28/02/24 | - |
Quarterly results
| Fiscal Period | December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Net sales Million USD | Released Forecast Spread | 14,7 11,8 24.58% | 11,7 9,37 24.43% | 12,7 10,4 21.42% | 6,58 11,0 -40.15% | 10,7 9,70 9.94% | 13,5 11,3 19.55% | 10,5 11,4 -7.83% | 11,0 10,4 5.97% | 8,94 10,1 -11.39% | 8,34 | 7,99 | 8,61 | 8,66 | 6,08 |
|
EBITDA Million USD | Released Forecast Spread | -47,0 -42,9 -9.42% | -47,4 | -46,9 | -43,9 | -41,7 | |||||||||
|
EBIT Million USD | Released Forecast Spread | -22,9 -25,9 11.63% | -27,1 -28,3 4.48% | -31,1 -28,1 -10.77% | -48,2 -33,1 -45.74% | -53,7 -44,3 -21.07% | -36,8 -49,4 25.54% | -33,9 -44,0 22.95% | -38,4 -38,9 1.32% | -47,5 -41,9 -13.37% | -47,9 | -51,0 | -53,2 | -56,4 | |
|
Earnings before Tax (EBT) Million USD | Released Forecast Spread | -14,3 -25,2 43.37% | -18,8 -27,1 30.8% | -5,58 -27,2 79.5% | -24,3 -29,0 16.26% | -81,6 -40,4 -101.79% | -40,2 -46,8 14.19% | -30,5 -41,1 25.65% | -21,9 -36,0 39.22% | -59,1 -40,7 -45.21% | -44,4 | -48,1 | -50,4 | -53,7 | |
|
Net income Million USD | Released Forecast Spread | -14,4 -24,2 40.34% | -18,9 -27,7 31.71% | -5,71 -28,4 79.88% | -24,6 -28,5 13.63% | -82,0 -40,1 -104.24% | -39,7 -47,4 16.17% | -32,0 -40,9 21.69% | -23,0 -35,8 35.69% | -60,2 -38,8 -55.07% | -45,0 | -48,8 | -51,1 | -54,9 | |
|
EPS USD | Released Forecast Spread | -0,34 -0,61 44.36% | -0,43 -0,65 33.55% | -0,13 -0,61 78.84% | -0,53 -0,61 13.65% | -1,81 -0,85 -113.49% | -0,86 -1,03 16.86% | -0,66 -0,87 24.29% | -0,43 -0,70 38.34% | -1,09 -0,70 -54.95% | -0,79 | -0,86 | -0,89 | -0,93 | -0,89 |
| Announcement Date | 28/02/22 | 09/05/22 | 08/08/22 | 03/11/22 | 28/02/23 | 04/05/23 | 07/08/23 | 02/11/23 | 28/02/24 | - | - | - | - | - |
More events
Past sector events for Merus N.V.
| 2024-04-12 | SINOCELLTECH GROUP LIMITED: Q4 2023 Earnings Release |
| 2024-04-10 07:00 am | NURIX THERAPEUTICS, INC.: Q1 2024 Earnings Release |
| 2024-04-08 | MABWELL (SHANGHAI) BIOSCIENCE CO., LTD.: Q4 2023 Earnings Release |
| 2024-04-02 03:06 am | TAIMED BIOLOGICS INC.: March 2024 Sales and Revenue Release |
| 2024-03-31 | PEPTRON, INC.: Q4 2023 Earnings Release (Projected) |
| 2024-03-31 | BIONEER CORPORATION: Q4 2023 Earnings Release (Projected) |
| 2024-03-29 08:30 am | INNOCARE PHARMA LIMITED: Q4 2023 Earnings Release |
| 2024-03-28 | BIO-THERA SOLUTIONS, LTD.: Q4 2023 Earnings Release |
| 2024-03-28 04:05 pm | ACELYRIN, INC.: Q4 2023 Earnings Release |
| 2024-03-28 04:02 pm | IMMUNOME, INC.: Q4 2023 Earnings Release |
Net sales - Quarter - Rate of surprise
Quarterly earnings - Rate of surprise
Net sales - Annual - Rate of surprise
Annual profits - Rate of surprise
- Stock Market
- Equities
- MRUS Stock
- Calendar Merus N.V.
